Statin-induced Parkinson's syndrome;Statininduziertes Parkinson-syndrom

Nervenarzt

Volumn 74, Issue 8, 2003, Pages 726-727

  Muller Th ^a  

^a ST JOSEF HOSPITAL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PERGOLIDE; SELEGILINE; UBIQUINONE; HYPOCHOLESTEROLEMIC AGENT;

DRUG MECHANISM; HISTORY OF MEDICINE; HUMAN; LETTER; MYOPATHY; NEUROPATHOLOGY; PARKINSONISM; CHEMICALLY INDUCED DISORDER; MUSCLE DISEASE; NOTE; RHABDOMYOLYSIS;

ANTICHOLESTEREMIC AGENTS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOVASTATIN; MUSCULAR DISEASES; PARKINSONIAN DISORDERS; RHABDOMYOLYSIS;

EID: 0041932290     PISSN: 00282804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00115-003-1528-z     Document Type: Letter

References (13)

1. FinstererJ (2003) Fibrat-/Statin-Myopathie. Nervenarzt 74:115-122
2. Müller T, Kuhn W, Pöhlau D, Przuntek H (1995) Parkinsonism unmasked by lovastatin. Ann Neurol 37:685-686
3. Simons M, Schwarzler F, Lutjohann D et al. (2002) Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: a 26-week randomized, placebo-controlled, double-blind trial. Ann Neurol 52:346-350
4. Folkers K, Langsjoen P, Willis R et al. (1990) Lovastatin decreases coenzyme Q levels in humans. Proc Natl Acad Sci U S A 87:8931-8934
5. Shults CW, Haas RH, Passov D, Beal MF (1997) Coenzyme QIO levels correlate with the activities of complexes I and II/III in mitochondria from parkinsonian and non-parkinsonian subjects. Ann Neurol 42:261-264
6. Rotig A, Appelkvist EL Geromel V et al. (2000) Quinone-responsive multiple respiratory-chain dysfunction due to widespread coenzyme QIO deficiency. Lancet 356:391-395
7. Schapira AH, Mann VM, Cooper JM, Krige D, Jenner PJ, Marsden CD (1992) Mitochondrial function in Parkinson's disease. The Royal Kings and Queens Parkinson's Disease Research Group. Ann Neurol 32 [Suppl]:116-124
8. Chan A, Reichmann H, Kogel A, Beck A, Gold R (1998) Metabolic changes in patients with mitochondrial myopathies and effects of coenzyme Q10 therapy. J Neurol 245:681-685
9. Haas RH, Nasirian F, Nakano K et al. (1995) Low platelet mitochondrial complex I and complex II/III activity in early untreated Parkinson's disease. Ann Neurol 37:714-722
10. Shults CW, Oakes D, Kieburtz K et al. (2002) Effects of coenzyme q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol 59:1541-1550
11. Fuente-Fernandez R, Stoessl AJ (2002) The biochemical bases for reward. Implications for the placebo effect. Eval Health Prof 25:387-398
12. Müller T, Buttner T, Gholipour A, Kuhn W (2003) Coenzyme Qlo supplementation mildly improves treated patients with Parkinson's disease. Neuroscience Letters 8; 341(3):201-204
13. Feigin A, Kieburtz K, Como P et al. (1996) Assessment of coenzyme Q10 tolerability in Huntington's disease. Mov Disord 11:321-323